Article Text

Download PDFPDF
Ribociclib-induced extensive vitiligo-like lesions: possible pathomechanisms with clinical, dermoscopic and histological correlation
  1. Gopikrishnan Anjaneyan1,
  2. Pavithran Keechilat2,
  3. Prasanna Duraisamy1 and
  4. Malini Eapen3
  1. 1Department of Dermatology, Amrita Institute of Medical Sciences and Research Centre, Cochin, Kerala, India
  2. 2Medical Oncology, Amrita Institute of Medical Sciences and Research Centre, Cochin, Kerala, India
  3. 3Department of Pathology, Amrita Institute of Medical Sciences and Research Centre, Cochin, Kerala, India
  1. Correspondence to Dr Gopikrishnan Anjaneyan; drgopikrishnana{at}gmail.com

Abstract

Cyclin dependent kinase (CDK) 4/6 inhibitors are targeted agents which act on cyclin-D and these combined with hormonal therapy have been approved for the treatment of locally advanced or metastatic breast cancer. CDK 4/6 inhibitors have been found to have a tolerable adverse event profile; however, they have been associated with various dermatological adverse events. We report a case of ribociclib-induced vitiligo and discuss the clinical, dermoscopic and histological features with a review of the various possible pathomechanisms involved.

  • Dermatology
  • Oncology
  • Breast cancer
  • Chemotherapy
  • Drugs and medicines

Statistics from Altmetric.com

Footnotes

  • Contributors GA and PK conceived and developed the theory and supervised this work. GA and PD wrote the manuscript with support from PK and ME. ME provided all the information about pathology and the images. All authors discussed and contributed to the final manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Case reports provide a valuable learning resource for the scientific community and can indicate areas of interest for future research. They should not be used in isolation to guide treatment choices or public health policy.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.